~~<i id='AFB3733425'><strike id='AFB3733425'><tt id='AFB3733425'><pre id='AFB3733425'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：comprehensive 2025-09-28 06:23:56 Page View：234

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Study links childhood stress with decline in older age
Next article： ChatGPT in medicine: STAT answers readers' burning questions

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

2 officers injured in shooting in Orlando, police say

1:29Policelightsonastreetatnight.STOCKPHOTO/GettyImagesTwopoliceofficerswerecriticallyinjuredonFrida

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

H.R. 3 is the wrong path to lower drug costs

Fromleft,Rep.RichardNeal(D-Mass.)speaksasRep.FrankPallone(D-N.J.)andHouseSpeakerNancyPelosi(D-Calif.